Tony Mok, M.D., professor, Division of Clinical Oncology, The Chinese University of Hong Kong, and senior investigator of the Phase 1b/2 trial commented, The Phase 1b data present that the combination of ficlatuzumab and gefinitib demonstrated promising medical activity and was well tolerated in patients. These data are encouraging as we continue steadily to evaluate ficlatuzumab in combination with gefinitib in patients with both wild-type and mutant EGFR NSCLC in the ongoing Stage 2 trial.Identifying the structure of telomerase allows the design of therapies to inactivate this enzyme in cancers and prevent the immortalization that tumor cells have developed. Cancer Prevention Jane McElroy, PhD of the University of Missouri, Columbia is studying the chance of endometrial cancer since it pertains to cadmium body burden amounts, as measured by the quantity of cadmium in urine. Her research seeks to research cadmium exposure and endometrial tumor risk in a population-based case-control study. Dorothy Apollonio, PhD, at the University of California at San Francisco is investigating how emerging research could be translated effectively to community decision-makers so that effective tobacco control polices could be created for marginalized populations, such as for example those with mental illness and/or substance abuse complications.